|
|
Article: Peplin Results for the Financial Year Ended 30 June 2009.(Financial report)
- Article from:
- Business Wire
- Article date:
- August 31, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Cash balance of US$17.7 million
* Positive results in first Phase 3 trial
* Initiated and completed enrollment in four Phase 3 trials
EMERYVILLE, Calif. & BRISBANE, Australia -- Peplin, Inc. (ASX:PLI) today announced financial results for the year ended 30 June 2009, reporting a US$17.7 million cash balance. Peplin will use these funds to complete Phase 3 clinical trials for its lead product, PEP005 (ingenol mebutate) Gel for actinic (solar) keratosis (AK). The company is confident it will have access to sufficient working capital to fund operations through its planned New Drug Application (NDA) filing with the Food and Drug Administration ...